Expertise in
1
conditions

Pascal Hutin

Quimper, FR 
Expertise in
1
conditions
Quimper, FR 

Overview

Pascal Hutin practices practicing medicine in Quimper, France.

Mr. Hutin is highly rated in 1 condition, according to our data. His clinical expertise encompasses Febrile Neutropenia, Orbital Pseudotumor, Myelofibrosis, and Agranulocytosis.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Quimper, France
Other Locations
Brest, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients
Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients
Enrollment Status: Completed
Publish Date: August 30, 2023
Intervention Type: Other
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)
Enrollment Status: Completed
Publish Date: October 04, 2022
Intervention Type: Drug
Study Phase: Phase 2
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association
Enrollment Status: Completed
Publish Date: April 13, 2021
Intervention Type: Drug
Study Drugs: Lenalidomide, Rituximab
Study Phase: Phase 3
View 2 Less Clinical Trials

13 Total Publications

The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.
The humoral response of mRNA COVID-19 vaccine in hematological diseases: The HEMVACO study.
Journal: Infectious diseases now
Published: January 03, 2022

Frequently Asked Questions about Pascal Hutin

Is Pascal Hutin a top-rated expert for Febrile Neutropenia?

MediFind is an objective health platform that identifies experts based on real-world data. Pascal Hutin is classified as an Advanced expert for Febrile Neutropenia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Pascal Hutin participate in research or clinical trials?

Yes. Pascal Hutin has published 13 articles and abstracts on conditions like Febrile Neutropenia. You can view a list of Pascal Hutin's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hutin's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile